John G Ullman & Associates Inc. Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

John G Ullman & Associates Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 94.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,430 shares of the biopharmaceutical company's stock after purchasing an additional 3,115 shares during the quarter. John G Ullman & Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $4,078,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. Curat Global LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $32,000. Finally, American National Bank & Trust purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $44,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on REGN shares. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. UBS Group boosted their price objective on Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a "neutral" rating in a research note on Friday, July 11th. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Stock Down 0.3%

REGN stock traded down $1.54 during midday trading on Friday, hitting $563.10. The company's stock had a trading volume of 755,785 shares, compared to its average volume of 906,903. The firm has a 50-day simple moving average of $542.56 and a 200-day simple moving average of $609.57. The firm has a market capitalization of $60.79 billion, a P/E ratio of 14.34, a PEG ratio of 2.11 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the firm earned $9.55 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.